Markers of b-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes
Markers of b-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes
复制标题
b 细胞衰竭标志物预示 2 型糖尿病患者对 GLP-1 受体激动剂治疗的血糖反应不佳
DOI：
--
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
A. Hattersley
中科院分区：
文献类型：
--
作者：
A. Jones;T. Mcdonald;B. Shields;A. Hill;C. Hyde;B. Knight;A. Hattersley
研究设计与方法我们前瞻性地研究了620名2型糖尿病患者，作为他们日常糖尿病护理的一部分，开始接受‡-1RA治疗的糖化血红蛋白58mmo1/m ol(7.5%)，并评估了6个月的治疗反应。我们使用线性回归和方差分析评估了与b细胞衰竭相关的基线临床测量和血糖反应(主要结果HbA1c变化0-6个月)与体重变化(0-6个月)之间的关系，并对基线HbA1c和联合治疗变化进行了调整。
RESEARCH DESIGN AND METHODS We prospectively studied 620 participants with type 2 diabetes and HbA1c ‡58 mmol/mol (7.5%) commencing GLP-1RA therapy as part of their usual diabetes care and assessed response to therapy over 6 months. We assessed the association between baseline clinical measurements associated with b-cell failure and glycemic response (primary outcome HbA1c change 0–6 months) with change in weight (0–6 months) as a secondary outcome using linear regression and ANOVA with adjustment for baseline HbA1c and cotreatment change.